Global CDMO Growth Bora operates ten CGMP facilities across Asia and North America and serves 100+ markets, indicating a broad capacity to scale manufacturing for multi-region launches and complex dose forms.

Strategic Partnerships Recent high-profile collaborations and asset acquisitions (Insilico alliance, MacroGenics asset purchase, expanded Montgomery and Rockville facilities) suggest Bora can support joint development programs and supply by integrating biologics and antibody-based therapies.

Biologics & High-Value Ops Expansion into biologics manufacturing in Maryland and increased GMP capacity imply opportunity to pursue biologics, complex injectables, and multi-formulation programs for late-stage and commercial needs.

Geographic Footprint Presence in the US, Europe, Japan, Canada, and the UK with recent facility expansions positions Bora to streamline global supply chains, reduce lead times, and support regional regulatory strategies.

Innovation & Recognition Being named a TIME World’s Most Impactful Company and leveraging AI-driven partnerships signals a value proposition around advanced manufacturing, digital collaboration, and scalable, tech-enabled CDMO services.